newsfilter
← Latest News
GlobeNewswire·

Context Therapeutics Reports Second Quarter 2025 Operating and Financial Results

CTIM-76 and CT-95 Phase 1 dose-escalation studies ongoing Cash and cash equivalents of $83.5 million as of June 30, 2025 Company expects its cash and cash equivalents will continue to fund operations into 2027